Webcasts Event RSS
Upcoming Events Past Events
HALO-301 Trial Update
November 26, 2018
View the live Webcast
Halozyme to Host Third Quarter 2018 Financial Results Conference Call
November 6, 2018
View the live Webcast
Cantor Fitzgerald Global Healthcare Conference
October 1, 2018
View the live Webcast

Investor Materials

Thumb Date Download
July 20, 2018 Corporate Presentation 973 KB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival 11/26/18
Halozyme Reports Third Quarter 2018 Financial Results 11/06/18
Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications 11/06/18
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties 10/30/18
See More

Stock Quote

HALO (NASDAQ) $15.17 -0.08 -0.53% Volume: 578,917 Pricing delayed 20 minutes December 14, 2018

Investor Contacts

Al Kildani
Vice President, Investor Relations
& Corporate Communications
Phone: 858-704-8122
Email: akildani@halozyme.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

November 26, 2018 Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival
November 6, 2018 Halozyme Reports Third Quarter 2018 Financial Results
November 6, 2018 Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications
Copyright © 2015-2017 . Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.14.0.5

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok